<DOC>
	<DOCNO>NCT02436460</DOCNO>
	<brief_summary>This study establish safety , determine improvement steroid refractory acute graft-vs-host disease ( aGvHD ) compare historical cohort , determine change aGvHD-associated T-cell clone patient steroid-refractory aGVHD follow allogeneic hematopoietic cell transplantation administer AbGn-168H weekly 4 week .</brief_summary>
	<brief_title>A Study AbGn-168H Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant</brief_title>
	<detailed_description>AbGn-168H humanize monoclonal antibody . This dose escalation study use modify toxicity probability interval method . AbGn-168H administer intravenously ( IV ) weekly four week , patient steroid refractory aGVHD follow hematopoietic cell transplant ( HCT ) . After completion study treatment , patient follow 90 days.The primary objective study establish safety , secondary objective study determine improvement disease response 3 month diagnosis steroid refractory aGVHD compare historical cohort determine change frequency and/or phenotype aGVHD-associated T cell clone response AbGn-168H therapy .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>1 . Diagnosis skin , gut and/or liver steroidrefractory GVHD clinical assessment treat physician follow allogeneic HCT . Patients fail respond steroid 7 day consider steroidrefractory 2 . Previouslytreated condition regimen GVHD immune suppression prophylaxis formulation steroid , except note Exclusion Criteria # 2 . 3 . AbGn168H ( neihulizumab ) therapy begin 14 day diagnosis aGvHD 4 . Karnofsky Performance Status ( KPS ) &gt; 50 % 5 . No evidence HCT graft failure multiorgan failure 6 . Ability understand willingness sign write informed consent document 1 . Uncontrolled infection responsive antimicrobial therapy require intensive critical care 2 . Progressive malignant disease , include posttransplant lymphoproliferative disease unresponsive therapy 3 . Treatment investigational GVHD prophylactic agent ( eg , CCR5 inhibitor ; lenalidomide ; and/or bortezomib ) within 7 day prior 1st dose neihulizumab 4 . Treatment investigational agent within prior 7 day prior 1st dose AbGn168H ( neihulizumab ) 5 . CMV PCR &gt; 500 copies/mL evidence endorgan damage due CMV 6 . Pregnant nursing 7 . HIV positivity ( NOTE : patient positive hepatitis B hepatitis C exclude , may evaluate casebycase basis ) 8 . Renal clearance CCR &lt; 40 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>